Ceribell (NASDAQ: CBLL) saw its stock price surge 5.04% in after-hours trading on Tuesday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.
The medical technology company reported quarterly revenue of $21.2 million, surpassing analyst expectations of $20.528 million by 3.27%. Ceribell also posted a narrower-than-expected loss per share of $(0.38), beating the consensus estimate of $(0.40) by 4.52%.
Adding to the positive sentiment, Ceribell raised its 2025 revenue guidance to a range of $85-$88 million, signaling strong confidence in its growth trajectory. This combination of better-than-expected current performance and improved future outlook appears to be driving investor enthusiasm, resulting in the significant after-hours stock price increase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.